Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.
Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.
复制标题
健康个体接种MVA-BN疫苗后猴痘病毒中和抗体水平低。
DOI：
10.1038/s41591-022-02090-w
复制
发表时间：
2023-01
期刊：
影响因子：
82.9
通讯作者：
de Vries, Rory D.
中科院分区：
文献类型：
--
作者：
Zaeck, Luca M.;Lamers, Mart M.;Verstrepen, Babs E.;Bestebroer, Theo M.;van Royen, Martin E.;Gotz, Hannelore;Shamier, Marc C.;van Leeuwen, Leanne P. M.;Schmitz, Katharina S.;Alblas, Kimberley;van Efferen, Suzanne;Bogers, Susanne;Scherbeijn, Sandra;Rimmelzwaan, Guus F.;van Gorp, Eric C. M.;Koopmans, Marion P. G.;Haagmans, Bart L.;GeurtsvanKessel, Corine H.;de Vries, Rory D.
于二零二二年七月，持续的猴痘（MPX）爆发被宣布为国际关注的突发公共卫生事件。改良的安卡拉-巴伐利亚北欧牛痘（MVA-BN，也称为Imvamune，JYNNEOS或Imvanex）是第三代天花疫苗，已被授权并用作MPX疫苗。迄今为止，没有数据显示接种疫苗的个体中存在MPX病毒（MPXV）中和抗体，也没有针对MPX的疫苗效力。在这里，我们表明，MPXV中和抗体可以检测到MPXV感染后和历史天花疫苗接种后。然而，在非致敏个体中的两次注射MVA-BN免疫系列产生相对低水平的MPXV中和抗体。基于MVA的流感疫苗的剂量节省导致较低的MPXV中和抗体水平，而使用相同的基于MVA的疫苗的第三次接种显著增强抗体应答。由于MPXV中和抗体作为预防疾病和传播性的相关性的作用目前尚不清楚，我们得出结论，接种疫苗的个体的队列研究是必要的，以评估疫苗在高危人群中的有效性。历史天花疫苗接种和猴痘病毒（MPXV）感染引起MPXV中和抗体，但接种MVA-BN后，MPXV中和抗体的频率较低，强度较低，MVA-BN是批准用于预防MPXV和天花的疫苗。
In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara—Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that is authorized and in use as a vaccine against MPX. To date, there are no data showing MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals nor vaccine efficacy against MPX. Here we show that MPXV-neutralizing antibodies can be detected after MPXV infection and after historic smallpox vaccination. However, a two-shot MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV-neutralizing antibodies. Dose-sparing of an MVA-based influenza vaccine leads to lower MPXV-neutralizing antibody levels, whereas a third vaccination with the same MVA-based vaccine significantly boosts the antibody response. As the role of MPXV-neutralizing antibodies as a correlate of protection against disease and transmissibility is currently unclear, we conclude that cohort studies following vaccinated individuals are necessary to assess vaccine efficacy in at-risk populations. Historic smallpox vaccination and monkeypox virus (MPXV) infection elicit MPXV-neutralizing antibodies, but MPXV-neutralizing antibodies are less frequent and of lower magnitude after vaccination with MVA-BN—the vaccine approved and in use for protection against MPXV and smallpox.
登录
查看更多内容
DOI：
10.1007/978-1-61779-876-4_4
发表时间：
2012-01-01
期刊：
Methods in molecular biology (Clifton, N.J.)
影响因子：
--
作者：
Kremer, Melanie;Volz, Asisa;Sutter, Gerd
通讯作者：
Sutter, Gerd
影响因子：
158.5
作者：
Thornhill, John P.;Barkati, Sapha;Orkin, Chloe M.
通讯作者：
Orkin, Chloe M.
DOI：
10.1073/pnas.0804985105
发表时间：
2008-08-05
影响因子：
11.1
作者：
Earl, Patricia L.;Americo, Jeffrey L.;Moss, Bernard
通讯作者：
Moss, Bernard
影响因子：
158.5
作者：
Pittman, Phillip R.;Hahn, Matthew;Chaplin, Paul
通讯作者：
Chaplin, Paul
影响因子：
--
作者：
Volz A;Sutter G
通讯作者：
Sutter G